Ribociclib (Kisqali), Ribociclib/Letrozole (Kisqali Femara)
Defines medical necessity criteria, initial and continuation approval rules, dosing limits, product availability, and coverage exclusions for ribociclib (Kisqali) and the co-pack ribociclib/letrozole (Kisqali Femara) for Commercial, HIM, and Medicaid lines of business affiliated with Centene.
Added requirement that Kisqali in combination with an aromatase inhibitor should be for initial endocrine-based therapy per FDA/NCCN and added ovarian ablation/suppression requirement for premenopausal women.
Added criteria for endometrial carcinoma as an off-label indication supported by NCCN compendium and guidelines.
Updated FDA approved indication for Kisqali with fulvestrant to 'adults' (population expansion).
Clarified maximum dosing for Kisqali and Kisqali Femara separating dosing into initial and continued therapy sections.
Extended approval duration from 6 months to 12 months for HIM and Medicaid (4Q2025 annual review).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.